Sean Maduck - 01 May 2025 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
Issuer symbol
CORT
Transactions as of
01 May 2025
Net transactions value
-$2,643,749
Form type
4
Filing time
05 May 2025, 20:33:21 UTC
Previous filing
02 Apr 2025
Next filing
04 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Maduck Sean Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck 05 May 2025 0001698310

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Options Exercise $64,923 +12,856 +15% $5.05 98,478 01 May 2025 Direct F1
transaction CORT Common Stock Sale $924,818 -12,856 -13% $71.94 85,622 01 May 2025 Direct F1, F2, F3
transaction CORT Common Stock Options Exercise $134,098 +26,554 +31% $5.05 112,176 02 May 2025 Direct F1
transaction CORT Common Stock Sale $1,866,355 -25,847 -23% $72.21 86,329 02 May 2025 Direct F1, F2, F4
transaction CORT Common Stock Sale $51,596 -707 -0.82% $72.98 85,622 02 May 2025 Direct F1, F2, F5
holding CORT Common Stock 10,000 01 May 2025 See Footnote F6
holding CORT Common Stock 10,000 01 May 2025 See Footnote F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -12,856 -11% $0.000000 108,540 01 May 2025 Common Stock 12,856 $5.05 Direct F8
transaction CORT Stock option (right to buy) Options Exercise $0 -26,554 -24% $0.000000 81,986 02 May 2025 Common Stock 26,554 $5.05 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2 This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.
F3 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $71.88 to $72.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $71.88 to $72.82 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $72.95 to $73.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6 Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F7 Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F8 Fully exercisable.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.